Harnessing AI in Pharmacovigilance: Using Technology as an Enabler Across the Clinical Development – Post-Marketing Continuum

Artificial intelligence (AI) is poised to have a transformative impact across the entire drug development continuum from preclinical research to post-marketing support.

When implemented appropriately, AI-driven technologies, from natural language processing and predictive analytics to machine learning algorithms, can streamline workflows, enhance signal detection and improve risk management. The key to effectively harnessing AI in life sciences is understanding the obstacles to be overcome and how technology can be used to mitigate those challenges.

Pharmacovigilance (PV) is an area of drug development that is prime for AI transformation. Confronted with an increasing volume and velocity of data that must be sourced from diverse channels, case processors are challenged to maintain accuracy, speed and regulatory compliance. Leveraging AI as an enabler to optimize the aspects of PV that are onerous streamlines intake and tracking, reserving human resources for the work that requires human intervention.

This webinar will explore the effective use of AI across the clinical development–post-marketing continuum, with a focus on how process automation and tech-enabled innovation is reshaping the landscape of PV. The key topics will include:

• Current trends in AI for drug development
• Challenges of PV
• AI solutions for streamlining post-market safety monitoring
• Future opportunities for AI in the clinical development–post-marketing continuum

Register for this webinar to stay ahead of AI advancements in life sciences and learn how to integrate innovative solutions into drug development strategies.

Speaker

Anna Russo, VP Machine Learning and Artificial Intelligence, Ergomed

With over 15 years of experience in Data Science and Artificial Intelligence, Anna brings a wealth of expertise and a track record of innovation. Her diverse career spans industries including healthcare, luxury, travel, and media, where she has successfully led AI-driven initiatives that enhance decision-making and operational efficiency.

In her current role, Anna is responsible for leading Data, AI, and ML strategy. She focuses on optimizing processes, delivering actionable insights, and driving innovation across clinical trials and pharmacovigilance. Her leadership and deep expertise advance global healthcare through transformative, cutting-edge solutions.

Message Presenter